Monopar Therapeutics 8-K filings

Monopar Therapeutics has successfully regained compliance with Nasdaq's minimum bid price rule after its stock price closed above $1.00 for ten consecutive trading sessions.

Monopar Therapeutics has received Human Research Ethics Committee clearance in Australia to begin a Phase 1 therapeutic trial of its radiopharmaceutical MNPR-101-Lu.

Monopar Therapeutics has successfully dosed the first patient in its Phase 1 clinical trial for MNPR-101-Zr, a uPAR-targeted imaging radiopharmaceutical, with positive initial safety and biodistribution results.

Monopar Therapeutics announced a 1-for-5 reverse stock split to regain Nasdaq compliance, along with its second quarter 2024 financial results and updates on its clinical programs.

Monopar Therapeutics has announced the enrollment of the first patient in a Phase 1 clinical trial for its novel radiopharmaceutical MNPR-101-Zr, targeting advanced cancers.

Monopar Therapeutics and NorthStar Medical Radioisotopes have amended and expanded their collaboration, securing a long-term supply of actinium-225 for Monopar's radiopharma development programs.

Monopar Therapeutics announced the presentation of preclinical data for its MNPR-101-Zr radiopharma program at the 2024 SNMMI Annual Meeting, highlighting its potential as a cancer treatment.

Monopar Therapeutics has announced the retirement of its CFO, Kim R. Tsuchimoto, and the appointment of Karthik Radhakrishnan as her successor, effective July 1, 2024.

Monopar Therapeutics announced its first quarter 2024 financial results and a strategic shift to focus on its radiopharmaceutical pipeline, including the initiation of a Phase 1 clinical trial for MNPR-101-Zr.

Monopar Therapeutics has filed a provisional patent application to protect recent advancements in its MNPR-101 radiopharmaceutical program.

Monopar Therapeutics has commenced a Phase 1 clinical trial for its radiopharmaceutical imaging agent MNPR-101-Zr, targeting advanced cancers.

Monopar Therapeutics reported its fourth quarter and full-year 2023 financial results, highlighted by progress in its MNPR-101 radiopharmaceutical program and ongoing clinical trials.

Monopar Therapeutics Inc. has released a radiopharma presentation, now accessible on the investor relations section of their website.

Monopar Therapeutics has released positive preclinical imaging data showing strong tumor uptake of its MNPR-101 radiopharmaceutical, supporting its potential for cancer treatment.

Monopar Therapeutics has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement, extending the deadline to August 26, 2024.

Monopar Therapeutics has appointed Professor Rodney Hicks as the lead investigator for their MNPR-101-Zr Phase 1 dosimetry clinical trial in advanced cancer patients.

Monopar Therapeutics has released promising preclinical data for its MNPR-101 radiopharmaceutical program, showing significant tumor uptake and therapeutic efficacy in advanced cancers.

Monopar Therapeutics has received ethics clearance in Australia to begin a Phase 1 trial of its radiopharmaceutical MNPR-101-Zr in patients with advanced cancers.